No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Viridian Therapeutics, Inc. operates as a biotechnology firm dedicated to developing treatments for patients grappling with serious medical conditions. Central to their pipeline are several investigational therapies targeting IGF-1R. This includes VRDN-001, a humanized monoclonal antibody currently advancing through Phase 1/2 clinical trials as a potential therapy for thyroid eye disease (TED). Additionally, VRDN-002, another IGF-1R antibody, is undergoing Phase 1 clinical evaluation. Their portfolio also features VRDN-003, a therapeutic antibody engineered to target IGF-1R, also intended for TED treatment. Known previously as Miragen Therapeutics, Inc., the company officially adopted the name Viridian Therapeutics, Inc. in January 2021. Founded in 2006, Viridian Therapeutics maintains its corporate headquarters in Waltham, Massachusetts.
www.viridiantherapeutics.comNo one on the platform currently holds 0K1R.L.
No tracked institution reports a position in 0K1R.L as of their last filing.
No one on the platform has traded 0K1R.L yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| Rev. Growth % | 23359.9% | 132.2% | ||||
| Profit Margin % | -483.6% | -31052.8% | -16829.8% | |||
| Free Cash Flow Margin % | -391.5% | -28724.1% | -14873.7% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $22M | -74.6% | $-3.93 | $-10.48–$-1.26 | — | 1 |
| 2027 | $232M | +967.7% | $-2.59 | $-6.91–$-0.83 | — | 1 |
| 2028 | $597M | +157.7% | $-0.33 | $-0.89–$-0.11 | — | 1 |
| 2029 | $874M | +46.5% | $1.33 | $0.43–$3.55 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 3 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-06 | $-1.03 | $-1.05 | -1.5% |
| 2026-05-05 | $-1.08 | $-0.90 | +16.7% |
| 2026-02-26 | $-0.98 | $-1.08 | -10.2% |
| 2025-11-05 | $-1.02 | $-0.34 | +66.6% |
| 2025-08-06 | $-1.01 | $-1.23 | -22.3% |
| 2025-05-06 | $-0.97 | $-1.07 | -10.5% |
| 2025-02-25 | $-1.04 | $-0.81 | +22.0% |
| 2024-11-12 | $-1.06 |
| $-1.15 |
| -9.2% |
| +18.19% |
| $5.3B |
| — |
| 0HQ1.LAzenta, Inc. | $33.44 | +0.42% | $1.5B | — |
| 0I8F.LDENTSPLY SIRONA Inc. | $10.11 | +0.80% | $2.0B | — |
Source: Financial Modeling Prep · peers by sector/industry